Ceftobiprol

Ceftobiprol Uses, Dosage, Side Effects, Food Interaction and all others data.

Ceftobiprol is a cephalosporin antibiotic with activity against methicillin-resistant Staphylococcus aureus. It was discovered by Basilea Pharmaceutica and is being developed by Johnson & Johnson Pharmaceutical Research and Development. Ceftobiprol is the first cephalosporin to demonstrate clinical efficacy in patients with infections due to methicillin-resistant staphylococci and, if approved by regulatory authorities, is expected to be a useful addition to the armamentarium of agents for the treatment of complicated skin infections and pneumonia.

Ceftobiprol, a cephalosporin antibiotic, is active against methicillin-resistant Staphylococcus aureus.

Ceftobiprol
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Ceftobiprol
Generic	Ceftobiprole
Ceftobiprole Other Names	Ceftobiprol, Ceftobiprole
Type
Formula	C₂₀H₂₂N₈O₆S₂
Weight	Average: 534.57 Monoisotopic: 534.110372808
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Ceftobiprol is a cephalosporin antibiotic used to treat both community and hospital-acquired pneumonia caused by susceptible bacteria.

For the treatment of serious bacterial infections in hospitalised patients.

Ceftobiprol is also used to associated treatment for these conditions: Community Acquired Pneumonia (CAP), Nosocomial Pneumonia

How Ceftobiprol works

Cephalosporins, such as ceftobiprole, are bactericidal and have the same mode of action as other beta-lactam antibiotics (such as penicillins). Cephalosporins disrupt the synthesis of the peptidoglycan layer of bacterial cell walls. The peptidoglycan layer is important for cell wall structural integrity, especially in Gram-positive organisms. The final transpeptidation step in the synthesis of the peptidoglycan is facilitated by transpeptidases known as penicillin binding proteins (PBPs). PBPs bind to the D-Ala-D-Ala at the end of muropeptides (peptidoglycan precursors) to crosslink the peptidoglycan. Beta-lactam antibiotics mimic this site and competitively inhibit PBP crosslinking of peptidoglycan.